Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 59,307 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 59,307 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $0.69, for a total value of $40,921.83. Following the sale, the director owned 2,782,650 shares in the company, valued at approximately $1,920,028.50. The trade was a 2.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Luke Evnin also recently made the following trade(s):

• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.06, for a total value of $39,330.24.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock traded down $0.03 during mid-day trading on Monday, hitting $0.62. 1,846,563 shares of the company were exchanged, compared to its average volume of 537,572. Werewolf Therapeutics, Inc. has a 12-month low of $0.56 and a 12-month high of $2.38. The company has a market capitalization of $30.15 million, a P/E ratio of -0.38 and a beta of 0.74. The business’s 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $1.29. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in Werewolf Therapeutics by 33.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the period. MPM Asset Management LLC grew its stake in shares of Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after buying an additional 25,688 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $92,000. Nuveen LLC purchased a new position in shares of Werewolf Therapeutics in the 1st quarter worth $71,000. Finally, MPM Bioimpact LLC raised its position in shares of Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on HOWL. Wedbush lowered shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research report on Friday, December 19th. Bank of America decreased their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Finally, HC Wainwright lowered their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, December 19th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.